Evidence map›Paper›PMID 37564637›Full record

ReviewFrontiers in immunology2023

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.

Aigli G Vakrakou, Eleni Karachaliou, Elisabeth Chroni, Vasiliki Zouvelou, Dimitrios Tzanetakos, Stavroula Salakou, Marianna Papadopoulou, Socrates Tzartos, Konstantinos Voumvourakis, Constantinos Kilidireas and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Aigli G VakrakouFirst Department of Neurology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Eleni KarachaliouSecond Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Elisabeth ChroniDepartment of Neurology, School of Medicine, University of Patras, Patras, Greece.
Vasiliki ZouvelouFirst Department of Neurology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Dimitrios TzanetakosSecond Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Stavroula SalakouSecond Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Marianna PapadopoulouSecond Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Socrates TzartosTzartos NeuroDiagnostics, Athens, Greece.
Konstantinos VoumvourakisSecond Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Constantinos KilidireasFirst Department of Neurology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Sotirios GiannopoulosSecond Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Georgios TsivgoulisSecond Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
John TzartosSecond Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRUniversity of Patras · GRUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature which attributes them their specific properties and pathogenic profile. On the other hand, acetylcholine receptor (AChR) MG, the most prevalent form of MG, is characterized by immunoglobulin (Ig)G1 and IgG3 antibodies to the AChR. IgG4 class autoantibodies are impotent to fix complement and only weakly bind Fc-receptors expressed on immune cells and exert their pathogenicity

Indexed as

Immunoglobulin GMyasthenia GravisAutoantibodiesHumansImmunotherapyReceptor Protein-Tyrosine KinasesReceptors, CholinergicAutoantibodiesImmunoglobulin GReceptor Protein-Tyrosine KinasesReceptors, Cholinergicanti-CD20CAAR-T cellsFcRnIgG4MuSKMyasthenia Gravis

Identifiers

PMID37564637
PMCPMC10410455
OpenAlexW4385324501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.